| 1. |
S African decision to end nevirapine monotherapy condemned |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Fondaparinux for DVT prevention: benefits at extra cost |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
IFN-β treatment cost driver in relapsing-remitting MS |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
COX-2s confer QOL benefit in clinical practice in Latin America |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 5-6
L Everitt,
Preview
|
|
摘要:
Randomised, controlled clinical trials have shown that Merck & Co's selective cyclo-oxygenase-2 (COX-2) inhibitors etoricoxib and rofecoxib are at least as effective as conventional non-selective NSAIDs as analgesic and anti-inflammatory agents. Researchers from North and South America set out to evaluate the effect of both agents on QOL and pain among patients treated in clinical practice for chronic low back pain or osteoarthritis in Latin American countries, and presented their results at the Annual European Congress of Rheumatology [Berlin, Germany; June 2004].1,2They found that improvements in pain and QOL were significantly greater following treatment with the COX-2 inhibitors compared with conventional NSAIDs.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Contraception unequivocally cost effective in the US |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Exenatide*is comparable to insulin glargine in terms of glycaemic control in patients with type 2 diabetes mellitus, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
A tetravalent meningococcal vaccine groups A C Y W-135*conjugate may prime the immune system and prevent meningococcal infection in infants, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Liposomal doxorubicin, paclitaxel in head and neck cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Citalopram improves symptoms of depression and reduces the frequency of seizures in patients with epilepsy, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Valsartan + HCTZ an advance on amlodipine in Black patients |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1448,
2004,
Page 11-12
C Innes,
Preview
|
|
摘要:
The combination of valsartan plus hydrochlorothiazide (HCTZ) has advantages over amlodipine in the treatment of hypertension in Black patients, according to a study presented at the 19th Annual Scientific Meeting of the American Society of Hypertension [New York, US; May 2004]. Comparable reductions in 24-hour ambulatory BP were observed in valsartan/HCTZ and amlodipine recipients. However, valsartan/HCTZ was superior to amlodipine at night and in non-dippers, whose BP is usually difficult to manage. Treatment with the combination also reduced levels of at least one inflammatory marker, and was associated with less oedema and joint swelling than amlodipine.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
